AFT Pharmaceuticals Ltd. | |
Stock Exchange | Australian Stock Exchange |
EPS |
AUD0.03 |
Market Cap |
AUD287.06 M |
Shares Outstanding |
97.31 M |
Public Float |
- |
AFT Pharmaceuticals Ltd. | |
Stock Exchange | New Zealand Stock Exchange |
EPS |
NZD0.03 |
Market Cap |
NZD299.71 M |
Shares Outstanding |
97.31 M |
Public Float |
10.3 M |
Address |
Nielsen House Auckland AU 0622 New Zealand |
Employees | - |
Website | http://www.aftpharm.com |
Updated | 07/08/2019 |
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. Its feature brands include Crystaderm, Maxigesic, Coco-Scalp, Maxiclear, Eyecare Hub, and Allergy Hub. It operates through the following geographical segments: Australia, New Zealand, Asia, and Rest of the World. |